Within the wide range of targets it aspires to address, Scholar Rock is currently pinning its hopes on these two growth factor-targeting therapies and betting on their novel approach—targeting latent forms to improve selectivity . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge